萤火虫荧光素酶单克隆抗体的制备与抗原决定簇的研究

以大肠杆菌表达的萤火虫荧光素酶 (fireflyluciferase)为抗原 ,免疫小鼠并进一步筛选与克隆 ,共得到 6株单克隆抗体 .制备腹水并纯化获得抗体后 ,对这 6株抗体与天然态和热变性态蛋白质以及蛋白酶解片段的结合性质进行了鉴定 .认为这 6株抗体的抗原决定簇都是顺序决定簇 .发现其中有 2株单抗与热变性态蛋白质及酶解片段的结合能力较强 ,而不与天然态蛋白质结合 ,其抗原决定簇可能是位于蛋白质内部的肽段 .另外 4株抗体既可与热变性态蛋白质以及酶解片段结合 ,也可与天然态蛋白质结合 ,其抗原决定簇可能位于蛋白质分子表面 .     

牛γ-干扰素在大肠杆菌中的表达及抗原性鉴定

目的在大肠杆菌中高效表达牛γ-干扰素（bovine interferon-γ,BovIFN-γ）,并对其生物活性进行初步鉴定。方法依据GenBank上基因序列人工合成BovIFN-γ基因,PCR方法扩增该基因,将其插入PET-28a载体构建原核表达质粒,转化大肠杆菌BL21中,在IPTG诱导下表达BovIFN-γ,并进行Western blot鉴定。Ni-NTA亲和层析法和电洗脱方法纯化表达的重组蛋白,用Western blot和商品化的BovIFN-γ检测试剂盒进行重组蛋白的抗原性检测。结果成功构建了BovIFN-γ原核表达载体PET-28a-BIFN-γ,并在大肠杆菌中高效表达,表达蛋白约占菌体总蛋白的32%,表达产物主要以可溶性形式存在于菌体裂解液上清中;重组蛋白可与BovIFN-γ单克隆抗体反应,Ni-NTA亲和层析法纯化的重组蛋白抗原活性比电洗脱方法纯化的抗原活性高。结论在大肠杆菌中成功表达了可溶性的BovIFN-γ蛋白,可与BovIFN-γ单抗发生反应,纯化的重组蛋白具有良好的反应原性。     

家蚕EGFR配体的鉴定和验证

表皮生长因子受体(EGFR)是广泛存在于后生动物中的多功能受体,其配体的种类、活化方式、配体与EGFR之间的相互作用以及激活的信号通路在哺乳动物中研究得较为深入。而非脊椎动物中,EGFR配体在各物种间差异较大,目前缺乏对除果蝇以外的其他昆虫EGFR配体的认识。通过同源比对、结构域预测、m RNA翻译起始序列分析和系统进化树构建,在家蚕中鉴定到2个EGFR的配体,命名为Bm EGF-1和Bm EGF-2。Bm EGF-1与果蝇Spitz有较高的同源性和一致的Rhomboid识别序列,Bm EGF-2为Vein的同源分子。经原核表达和纯化获得了Bm EGF-1胞外区段,利用Sf9细胞分泌Bm EGFR胞外区段,并通过pull-down实验验证了两者之间存在相互作用。在Bm E细胞中表达Bm EGF-1后,通过Western blotting检测到ERK和p38 MAPK的磷酸化水平增强,说明其不仅能激活经典的ERK信号通路,还可能通过p38 MAPK信号通路参与其他生理过程,为进一步研究EGFR配体在家蚕中的生物学功能提供了参考。     

人精子抗原决定簇的末端单糖参与小鼠IgA单抗与抗原的结合

研究消化道免疫后获得的抗人精子单抗(特别是IgA单抗)的靶抗原分子性质,有助于了解哪一些抗原可以通过消化道免疫,刺激机体产生局部分泌性兔疫反应。这对于抗精子避孕疫苗研制中精子有效抗原和免疫避孕投药途径的选择,阐明精子局部免疫的发生机制和弄清免疫性不育病人的病因有一定的意义。本文对消化道免疫获得的33个抗精子IgA单抗,12个IgG和35个IgM单抗靶抗原的生化性质及末端单糖做了鉴定。免疫印迹的结果显示,IgA,IgM和IgG类单抗靶抗原的分子量范围分别为10—89,11—75和12—94 KDa。有12个单抗的靶抗原为非蛋白类的糖复合物,一个IgA单抗(A 22)的靶抗原为不含糖的蛋白。凝集素封闭和糖苷酶消化试验的结果显示,98.7%单抗的靶抗原分子末端含一种或几种糖。五种凝集素对IgA类单抗靶抗原的封闭效应均较强,表明IgA类单抗靶抗原的抗原决定簇含有岩藻糖,乙酰氨基葡萄糖,乙酰氨基半乳精,半乳糖和甘露糖等末端单糖者较多。IgG类单抗靶抗原的抗原决定簇则含有带岩藻糖,乙酰氨基半乳糖和α-甘露糖等末端单糖者较多。内切-β-半乳糖苷酶消化试验的结果表明,54.4%IgA类单抗的靶抗原为依赖半乳糖苷连接的糖肽化合物。这些结果表明,经消化道免疫能产生IgA及其它类别抗体的绝大多数人精子抗原为含多种类型末端单糖的膜表面分子。     

一株人抗人A—血型物质单克隆抗体特异性的研究

本文对一株人抗人A-血型物质单克隆抗体,用定量免疫沉淀法以及ELISA研究其与多种单糖、双糖及寡糖的反应性,从而确定了其结合部位的结构特异性。实验发现其结合部位互补于含有双分子岩藻糖残基的A-t糖:这一研究进一步强调了含有双分子岩藻糖残基的A血型抗原决定簇的重要性。     

抗CEA免疫毒素的表达、纯化、复性与生物学活性的研究

以抗癌胚抗原（Carcinoembryonic antigen, CEA）单链抗体与假单胞菌外毒素（Pseudomonas exotoxin A, PEA）的截短和修饰形式PE38/KDEL构建重组免疫毒素CEA/PE38/KDEL,并在大肠杆菌菌株BL21(DE3)-star中表达。采用镍离子螯合层析法纯化变性的包涵体样品,并用连续梯度透析的方法对纯化后的包涵体进行复性。采用流式细胞术鉴定复性产物与靶细胞的结合活性,结果表明免疫毒素CEA/PE38/KDEL具有与靶细胞特异性结合的活性。以MTT法检测免疫毒素对肿瘤细胞的体外杀伤活性,结果表明该免疫毒素对SW1116和CNE_2细胞具有特异性杀伤活性。证明了经包涵体复性的抗CEA免疫毒素CEA/PE38/KDEL对表达CEA抗原的肿瘤细胞具有良好的结合和杀伤活性。     

乳腺癌单克隆抗体AF9抗原的特性及分布

对抗人乳腺癌单抗AF9识别的抗原特性及分布进行了研究,结果表明AF9抗原是由糖、脂及蛋白质组成的复合蛋白质,不耐热;AF9识别的抗原决定簇不存在于铁蛋白及癌胚抗原;蛋白质印迹检测表明AF9识别的抗原有4种成分,分子量分别为51 000,56 000,67 000,73 000.免疫组化ABC染色显示该抗原主要存在于乳腺癌细胞的胞浆及胞膜,在部分其它种类肿瘤组织中也可检测到,但在所检正常组织中未见到.AF9抗原可能是新的乳腺肿瘤相关抗原.     

苦荞过敏蛋白TB22的原核表达及纯化

为了确定苦荞主要过敏原蛋白TB22的抗原决定簇,揭示其致敏机制,为以后的分子改造及育种改良打下基础,需要在体外微生物体系中获得大量的纯化蛋白。以pQE31为表达载体,M15为表达菌株,使用IPTG诱导,在37℃获得了以包涵体形式存在的表达产物。经WesternBlotting检测,证明表达条带N端带有Histidinetag。使用8molL尿素初步纯化后,目的蛋白含量达到40%以上。进一步HitrapChelatingHP亲和纯化,表达蛋白的纯度达到90%以上。建立了适合重组TB22纯化的基本方法,得到了纯化的包涵体,为抗TB22抗体的制备及其抗原决定簇的研究奠定了基础。     

应用单克隆抗体免疫细胞化学法分析尸检组织中肾综合征出血热病毒G2，NP及HA结构蛋白抗原

本文应用15株分别抗肾综合征出血热(HFRS)病毒糖蛋白(Glycoprotein Ⅱ G2),核蛋白(Nuclcocapsid,NP)及血凝素(Hemagglutinin,HA)抗原的单克隆抗体免疫细胞化学方法对19例HFRS尸检病例的16种组织中的病毒抗原进行了定位和分布的研究及抗原分析。结果表明,死于早期HFRS人体组织内病毒抗原量大,分布广泛,主要以可溶性和颗粒性两种形式存在,前者存在于细胞内和细胞外,呈G2,NP及HA抗原阳性,是参与形成免疫复合物的主要抗原形式;后者是以单纯病毒NP或HA抗原阳性的病毒包涵体(IB)形式存在于细胞内,是病毒直接作用所致细胞病变的标志,IB的广泛分布但只有极个别阳性细胞发生坏死,说明该病毒具有泛嗜性感染和弱致细胞病变能力的特性。抗原分析结果显示,组织细胞中病毒抗原的表达及其抗原量受宿主细胞的种属,组织结构特点及病期的影响,也存在个体差异以及因感染病毒株或血清型不同产生差异的可能性。病毒抗原染色形态学证实,NP上具有HA抗原位点,其抗原决定簇有三类,其中的某些抗原决定簇可因病毒宿主动物或细胞的种属不同,表达也不同。HA抗原在人体组织细胞中的高表达和广泛分布也说明HFRSV对人体有很强的侵袭力。     

噬菌体展示文库及其应用

近十几年来,噬菌体展示技术得到了迅速的发展。通过展示随机肽库可用来筛选与特殊靶分子相结合的配基;模拟非蛋白的配基;也可用作确定抗体表位的工具。展示蛋白;或其功能结构的文库为我们提供了分析结构与功能关系的体系,并能产生具有改变结合位点或新的催化活性的蛋白。展示短的抗原决定簇的融合噬菌体为开发新的疫苗提供了基础,而表达抗体片段的文库则提供了一种产生单克隆抗体的方法。     

Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model

Radiolabeled peptides are emerging tools for diagnosis and therapy of tumors overexpressing receptors. However, binding to receptors expressed by nontumor tissues may cause toxicity. The objective of this study was to specifically enhance the binding affinity of labeled peptides to tumor cells, as opposed to receptor-positive nontumor cells, to ensure targeting selectivity. This was achieved by the simultaneous binding of hapten-bearing peptides to their receptor and to a tumor-associated antigen, mediated by a bispecific antibody directed to the tumor antigen and to the hapten. Binding of labeled neurotensin analogues bearing the DTPA(indium) hapten (NT-DTPA(111In)) to human colorectal carcinoma cells (HT29), which express the neurotensin receptor (NTR1) and carcinoembryonic antigen (CEA), was studied in the presence of a bispecific antibody (BsmAb) directed to CEA and to DTPA(indium). In vitro dual binding of NT-DTPA in the presence of BsmAb was about 6.5-fold higher than monovalent binding to NTR1 and 3.5-fold higher than the sum of the monovalent bindings to NTR1 or to CEA, suggesting cooperativity. Increased binding under bivalent conditions translated into increased internalization. In vivo pretargeting with BsmAb enhanced tumor uptake and tumor retention. Hapten bearing peptides binding simultaneously an overexpressed cell-surface receptor and a tumor antigen show increased selectivity to target tumor cells as compared to cells only expressing the cell surface receptor. Better resistance to enzymatic degradation and optimized administration protocols should further enhance in vivo targeting selectivity and may allow the development of radiopharmaceuticals labeled with isotopes suitable for radiotherapy such as 131I or 90Y.     

Current biomarkers of canine mammary tumors

Mammary tumors are the second most common neoplasia in dogs. Due to the high similarity of canine mammary tumors (CMT) to human breast cancers (HBC), human biomarkers of HBC are also detectable in cases of CMT. The evaluation of biomarkers enables clinical diagnoses, treatment options and prognosis for bitches suffering from this disease. The aim of this article is to give a short summary of the biomarkers of CMT based on current literature. Very promising biomarkers are miRNAs, cancer stem cells, and circulating tumor cells, as well as mutations of the breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2). Until now, the most studied and reliable biomarkers of CMT have remained antigen Ki-67 (Ki-67), endothelial growth factor receptor, human epidermal growth factor receptor 2 (HER-2), estrogen receptor, progesterone receptor and cyclooxygenase 1 (COX-2), which can be detected in both serum and tissue samples using different molecular methods. However, carcinoembryonic antigen and cancer antigen 15-3 (CA 15-3), while poorly studied, seem to be good biomarkers, especially for the early detection and prognosis of CMT. We will also mention the following: proliferative cell nuclear antigen, tumor protein p53 (p53), E-cadherin, vascular endothelial growth factor, microRNAs, cancer stem cells and circulating tumor cells, which can also be useful biomarkers. Although many studies have been conducted so far, the estimation of biomarkers in cases of CMT is still not a common practice, and more detailed research should be done.     

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody

Both the epidermal growth factor receptor (EGFR) and the insulin-like growth factor receptor (IGFR) have been implicated in the tumorigenesis of a variety of human cancers. Effective tumor inhibition has been achieved both experimentally and clinically with a number of strategies that antagonize either receptor activity. Here we constructed and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and IGFR, using two neutralizing human antibodies originally isolated from a phage display library. The BsAb not only retained the antigen binding capacity of each of the parent antibodies, but also were capable of binding to both targets simultaneously as demonstrated by a cross-linking enzyme-linked immunosorbent assay. Furthermore, the BsAb effectively blocked both ligands, EGF and IGF, from binding to their respective receptors, and inhibited tumor cell proliferation as potently as a combination of both the parent antibodies. More importantly, the BsAb were able to completely block activation of several major signal transduction molecules, including Akt and p44/p42 MAP kinases, by both EGF and IGF, whereas each individual parent antibody was only effective in inhibiting those signal molecules activated by the relevant single growth factor. The BsAb molecules retained good antigen binding activity after incubation with mouse serum at 37 degrees C for up to 6 days. Taken together, our results underscore the benefits of simultaneous targeting multiple growth factor receptor pathways for more efficacious cancer treatment. This report describes the first time use of a recombinant BsAb for targeting two tumor-associated molecules on either a single or adjacent tumor cells for enhanced antitumor activity.     

Cell-Type-Specific Gene Transfer into Human Cells with Retroviral Vectors That Display Single-Chain Antibodies

The successful application of human gene therapy protocols on a broad clinical basis will depend on the availability of in vivo cell-type-specific gene delivery systems. We have developed retroviral vector particles, derived from spleen necrosis virus (SNV), that display the antigen binding site of an antibody on the viral surface. Using retroviral vectors derived from SNV that displayed single-chain antibodies (scAs) directed against a carcinoembryonic antigen-cross-reacting cell surface protein, we have shown that an efficient, cell-type-specific gene delivery can be obtained. In this study, we tested whether other scAs displayed on SNV vector particles can also lead to cell-type-specific gene delivery. We displayed the following scAs on the retroviral surface: one directed against the human cell surface antigen Her2neu, which belongs to the epidermal growth factor receptor family; one directed against the stem cell-specific antigen CD34; and one directed against the transferrin receptor, which is expressed on liver cells and various other tissues. We show that retroviral vectors displaying these scAs are competent for infection in human cells which express the antigen recognized by the scA. Infectivity was cell type specific, and titers above 10⁵ CFU per ml of tissue culture supernatant medium were obtained. The density of the antigen on the target cell surface does not influence virus titers in vitro. Our data indicate that the SNV vector system is well suited for the development of a large variety of cell-type-specific targeting vectors.     

Growth inhibition of human nasopharyngeal carcinoma in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies

Monoclonal antibodies (MoAbs) were developed against epidermal growth factor (EGF) receptor on the human epidermoid carcinoma cell line A431. The A431 antigen recognized by the MoAbs has an apparent molecular weight of approximately 170,000, with the same molecular weight as the CNE-2 cell line (poorly differentiated nasopharyngeal carcinoma). Administration of anti-EGF receptor MoAbs inhibited tumor formation, caused by the CNE-2 and A431 cell lines, in athymic mice. When the same MoAbs were used in therapy against Tca8113 (a human tongue carcinoma) and HeLa cells (a human cervical carcinoma), tumor growth was not affected. The number of EGF receptors and the apparent dissociation constants for 125I-EGF on CNE-2 and A431 were 1.3 x 10(5)/cell (Kd 7.7 x 10(-8) M) and 1.4 x 10(6)/cell (Kd 2.4 x 10(-9) M), respectively. Three anti-EGF receptor MoAbs were used in these studies. MoAbs 3 and 176, capable of competing with EGF for receptor binding, showed significant tumor growth inhibition. MoAb 101 was incapable of blocking the binding of EGF to its receptor and was not as effective as MoAbs 3 and 176 in tumor growth inhibition. Our observation is that in vitro, MoAb anti-EGF receptor is cytostatic, rather than cytocidal, against CNE-2 and A431.     

Lymphocyte Display: A Novel Antibody Selection Platform Based on T Cell Activation

Since their onset, display technologies have proven useful for the selection of antibodies against a variety of targets; however, most of the antibodies selected with the currently available platforms need to be further modified for their use in humans, and are restricted to accessible antigens. Furthermore, these platforms are not well suited for in vivo selections. We present here a novel cell based antibody display platform, which takes advantage of the functional capabilities of T lymphocytes. The display of antibodies on the surface of T lymphocytes, as a part of a chimeric-immune receptor (CIR) mediating signaling, may ideally link the antigen-antibody interaction to a demonstrable change in T cell phenotype, due to subsequent expression of the early T cell activation marker CD69. In this proof-of-concept, an in vitro selection was carried out using a human T cell line lentiviral-transduced to express a tumor-specific CIR on the surface, against a human tumor cell line expressing the carcinoembryonic antigen. Based on an effective interaction between the CIR and the tumor antigen, we demonstrated that combining CIR-mediated activation with FACS sorting of CD69⁺ T cells, it is possible to isolate binders to tumor specific cell surface antigen, with an enrichment factor of at least 10³-fold after two rounds, resulting in a homogeneous population of T cells expressing tumor-specific CIRs.     

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity

Both the epidermal growth factor receptor (EGFR) and the insulin-like growth factor receptor (IGFR) have been implicated in the tumorigenesis of a variety of cancers. Here we propose that simultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor activity. To this end, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable regions from two antagonistic antibodies: IMC-11F8 to EGFR and IMC-A12 to IGFR. The Di-diabody binds to both EGFR and IGFR and effectively blocked both EGF- and IGF-stimulated receptor activation and tumor cell proliferation. The Di-diabody also inherited the biological properties from both of its parent antibodies; it triggers rapid and significant IGFR internalization and degradation and mediates effective antibody-dependent cellular cytotoxicity in a variety of tumor cells. Finally, the Di-diabody strongly inhibited the growth of two different human tumor xenografts in vivo. Our results underscore the benefits of simultaneous targeting of two tumor targets with bispecific antibodies.     

Synthetic peptide approach to the analysis of kinase activities of avian EGF receptor and v-erbB protein

Analysis of the structure and function of a protein such as the epidermal growth factor receptor is facilitated by the use of antibodies directed against discrete portions of the protein. Here, we describe the characterization and use of antibodies directed against synthetic peptides corresponding to specific portions of the epidermal growth factor receptor and/or v-erbB protein. In particular, one useful antiserum has allowed us to compare the protein kinase activities of the epidermal growth factor receptor and the v-erbB proteins and to conclude that the v-erbB protein is a protein-tyrosine specific kinase as is its homologue the avian epidermal growth factor receptor.     

Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity

Antibody (Ab) nucleophilic reactivity was studied using hapten and polypeptide antigens containing biotinylated phosphonate diester groups (covalently reactive antigen analogs, CRAs). Polyclonal IgG from healthy donors formed covalent adducts with a positively charged hapten CRA at levels superior to trypsin. Each of the 16 single chain Fv clones studied expressed a similar reactivity, indicating the V domain location of the nucleophiles and their broad distribution in diverse Abs. The formation of hapten CRA-Fv adducts was correlated with Fv proteolytic activity determined by cleavage of a model peptide substrate. Despite excellent nucleophilicity, proteolysis by IgG proceeded at lower rates than trypsin, suggesting that events occurring after nucleophilic attack on the substrate limit the rate of Ab proteolysis. The extracellular domain of the epidermal growth factor receptor with phosphonate diester groups at Lys side chains and a synthetic peptide corresponding to residues 421- 431 of human immunodeficiency virus glycoprotein (gp) 120 with the phosphonate diester at the C terminus formed covalent adducts with specific polyclonal and monoclonal Abs raised by immunization with epidermal growth factor receptor and synthetic gp120-(421- 436) devoid of phosphonate diester groups, respectively. Adduct formation was inhibited by extracellular domain of the epidermal growth factor receptor (exEGFB) and synthetic gp120-(421- 436) devoid of phosphonate groups, suggesting that the nucleophiles are located within the antigen binding sites. These results suggest the innate character of the Ab nucleophilic reactivity, its functional coordination with non-covalent adaptive binding interactions developing over the course of B cell maturation, and novel routes toward permanent inhibition of Abs.     

Identification of autophosphorylation sites of HER2/neu.

HER2 or c-erbB-2 is a putative growth factor receptor with sequence homology to the epidermal growth factor receptor. It is the human homologue of the rat protooncogene neu and may have an important role in human malignancies such as breast and ovarian cancers. Like other growth factor receptors, HER2 has intrinsic protein tyrosine kinase activity and undergoes autophosphorylation. Recently, we have demonstrated that, similar to the epidermal growth factor receptor, all autophosphorylation sites of HER2 are localized in the carboxyl terminus of this protein. In the present study, immunopurified HER2 was allowed to autophosphorylate, and tryptic phosphopeptides were generated. After purification of these phosphopeptides by high performance liquid chromatography, microsequencing was performed. Utilizing this approach, two autophosphorylation sites were unequivocally identified at Y1023 and Y1248. The sequences of two other tyrosine phosphorylated tryptic peptides were determined, but the exact site of autophosphorylation could not be determined because multiple tyrosines were located on each peptide. However, each of these peptides contains tyrosines that correspond to major autophosphorylation sites of the epidermal growth factor receptor, suggesting that, in addition to Y1023 and Y1248, Y1139 and Y1222 also serve as autophosphorylation sites of HER2.